Skip to main content
TipRanks
Go Ultimate75% OFF

Exagen (E08A) Stock Price & Analysis

0 Followers

E08A Stock Chart & Stats

€3.54€0.16(4.73%)
At close: 5:30 PM GMT+1
€2.5€5€7.5€10Mar 17Jan 18Apr 10Apr 17
Day’s Range
EUR 3.54 - EUR 3.54
52-Week Range
EUR 2.26 - EUR 7.60
Previous Close
EUR 3.38
Volume
N/A
Average Volume (3M)
4
Market Cap
EUR 88.36M
Enterprise Value
EUR 202.70M
Total Cash (Recent Filing)
EUR 28.09M
Total Debt (Recent Filing)
EUR 28.76M
Price to Earnings (P/E)
―
Beta
1.06
Next Earnings
Mar 16, 2027 (Est.)
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Strong Revenue Growth And Gross Margins

Rapid revenue expansion combined with stable gross margins indicates meaningful demand and sound test-level economics. If Exagen sustains growth while increasing operating leverage, the existing revenue base can support improving profitability and strengthen the company’s position in autoimmune diagnostics over the next several quarters.

Growing AVISE Adoption

A growing installed base of AVISE tests and ordering physicians supports recurring clinical utilization and broader market penetration. Continued adoption can reinforce physician familiarity, expand testing volume, and improve the durability of Exagen’s autoimmune diagnostics platform beyond short-term quarterly fluctuations.

Pipeline And Platform Expansion

Launching a differentiated myositis panel and expanding Pharma Services broaden Exagen beyond its established AVISE offering. The planned faster turnaround and wider biomarker menu could create additional clinical utility, while the services business provides another avenue for revenue diversification and platform growth.

Bears Say

Persistent Unprofitability

Despite strong top-line growth, Exagen remains materially loss-making, showing that current scale has not yet produced sustainable earnings. Continued operating losses could constrain reinvestment and leave the company dependent on further growth, cost discipline, and operating leverage to reach its targeted adjusted EBITDA breakeven.

Negative Cash Generation

Ongoing negative operating and free cash flow means the business is not yet self-funding its operations. Although burn has improved versus earlier periods, continued cash consumption can require financing and increase dilution or refinancing risk if revenue growth and margin improvement do not progress as planned.

Reimbursement And Payer Uncertainty

Exagen’s testing revenue depends on reimbursement and payer access, making unresolved policy and coverage issues a durable execution risk. Potential generic-code rate pressure and prolonged negotiations with payers could reduce realized revenue per test or delay adoption, complicating the path to profitability.

Exagen News

E08A FAQ

What was Exagen’s price range in the past 12 months?
Exagen lowest stock price was €2.26 and its highest was €7.60 in the past 12 months.
What is Exagen’s market cap?
Exagen’s market cap is €88.36M.
When is Exagen’s upcoming earnings report date?
Exagen’s next earnings report is estimated for Mar 16, 2027 (not yet confirmed), which is in 115 days.
How were Exagen’s earnings last quarter?
Exagen released its earnings results on Nov 10, 2026. The company reported -€0.227 earnings per share for the quarter, missing the consensus estimate of -€0.165 by -€0.062.
Is Exagen overvalued?
According to Wall Street analysts Exagen’s price is currently Undervalued.
Does Exagen pay dividends?
Exagen does not currently pay dividends.
What is Exagen’s EPS estimate?
Exagen’s EPS estimate is -0.17.
How many shares outstanding does Exagen have?
Exagen has 25,513,496 shares outstanding.
What happened to Exagen’s price movement after its last earnings report?
Exagen reported an EPS of -€0.227 in its last earnings report, missing expectations of -€0.165. Following the earnings report the stock price went up 21.569%.
Which hedge fund is a major shareholder of Exagen?
Hedge funds hold Exagen shares: the largest hedge-fund position in Exagen is 1,034,847,265 shares, and hedge funds increased their holdings by 181.7K shares last quarter.
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology